BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Raised to Sell at Wall Street Zen

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

BBOT has been the subject of a number of other reports. JPMorgan Chase & Co. assumed coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, July 8th. They set an “overweight” rating and a $27.00 price target for the company. UBS Group downgraded BridgeBio Oncology Therapeutics to an “overweight” rating in a research report on Wednesday, July 8th. Oppenheimer assumed coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. Finally, Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.80.

BridgeBio Oncology Therapeutics Trading Up 3.0%

Shares of NASDAQ:BBOT opened at $8.56 on Friday. The company has a market capitalization of $685.74 million, a price-to-earnings ratio of -4.18 and a beta of 0.39. The stock’s fifty day moving average is $8.16. BridgeBio Oncology Therapeutics has a fifty-two week low of $7.00 and a fifty-two week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. Equities research analysts anticipate that BridgeBio Oncology Therapeutics will post -2.3 EPS for the current year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at approximately $63,000. XTX Topco Ltd increased its position in shares of BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after purchasing an additional 5,249 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $107,000. Tema ETFs LLC raised its holdings in BridgeBio Oncology Therapeutics by 13.6% during the 2nd quarter. Tema ETFs LLC now owns 93,339 shares of the company’s stock valued at $711,000 after buying an additional 11,167 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $144,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.